STOCK TITAN

CorMedix Inc - CRMD STOCK NEWS

Welcome to our dedicated news page for CorMedix (Ticker: CRMD), a resource for investors and traders seeking the latest updates and insights on CorMedix.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect CorMedix's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of CorMedix's position in the market.

Rhea-AI Summary
CorMedix Inc. announced that CMS granted TDAPA to DefenCath, a critical step for the company's outpatient launch in July 2024. DefenCath is approved by the FDA to reduce CRBSIs in adult patients with kidney failure.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.58%
Tags
none
-
Rhea-AI Summary
CorMedix Inc. announces the U.S. inpatient commercial availability of DefenCath (Taurolidine and Heparin), a solution to reduce catheter-related bloodstream infections in adult patients with kidney failure. The company plans to expand to outpatient settings by July 1, 2024, pending CMS approval.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.88%
Tags
none
-
Rhea-AI Summary
CorMedix Inc. (CRMD) announces acceptance of two abstracts for presentation at the SHEA conference. The first abstract showcases taurolidine's broad antimicrobial activity against various bacteria, including NTM and fungal isolates. The second abstract highlights outcomes and economics of hospital-acquired bloodstream infections in hemodialysis patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
21.02%
Tags
none
Rhea-AI Summary
CorMedix Inc. (CRMD) secures a 5-year commercial supply contract with ARC Dialysis, for DefenCath®, a product approved under LPAD. The agreement aims to prevent infections in hemodialysis patients, showcasing CorMedix's commitment to innovation and partnership.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.06%
Tags
none
-
Rhea-AI Summary
CorMedix Inc. (CRMD) will participate in the Needham 23rd Annual Healthcare Conference, presenting at a fireside chat and investor meetings virtually on April 8 – 11, 2024. The company focuses on developing therapeutic products for life-threatening conditions. Investors can access the webcast and replay on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.22%
Tags
conferences
-
Rhea-AI Summary
CorMedix Inc. (CRMD) announces FDA approval for DefenCath, a catheter lock solution to reduce infections in kidney failure patients on hemodialysis. The company is preparing for commercial launch and has a strong financial position with $76.0 million in cash and short-term investments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.84%
Tags
Rhea-AI Summary
CorMedix Inc. (CRMD) will release its Q4 and full-year 2023 financial results on March 12, 2024, followed by a corporate update conference call. The company focuses on developing therapeutic products for life-threatening conditions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.13%
Tags
conferences earnings
-
Rhea-AI Summary
CorMedix Inc. announced updates related to the anticipated launch of DefenCath, a therapeutic product for the prevention and treatment of life-threatening diseases. The Center for Medicare & Medicaid Services (CMS) has determined that DefenCath will be eligible for reimbursement under the ESRD PPS, allowing CorMedix to submit an application for a Transitional Drug Add-On Payment (TDAPA) for five years of additional payment reimbursement to outpatient providers. The list price for DefenCath has been set at $249.99 per 3ml vial, with a commitment to reduce the list price if eligible for Medicare Part B reimbursement. CorMedix also received a New Technology Add-On Payment (NTAP) for inpatient reimbursement and plans to launch commercialization on April 15, 2024 for inpatient and July 1, 2024 for outpatient, contingent upon CMS approval and implementation of the TDAPA application.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.27%
Tags
none
-
Rhea-AI Summary
CorMedix Inc. (CRMD) announces commercial and operational updates related to the anticipated launch of DefenCath®. The company submitted an HCPCS application for a J-Code to CMS for DefenCath, with a commercial availability estimate of April 15, 2024 for the inpatient setting and no sooner than July 1, 2024 for the outpatient setting. Significant interest from providers has been received, with several large and medium-sized health systems committing to put DefenCath through their P&T formulary processes in 2024. CorMedix believes it has sufficient resources to fund the commercial launch.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.49%
Tags
none
Rhea-AI Summary
CorMedix Inc. (Nasdaq: CRMD) appoints Beth Zelnick Kaufman, Esq. as EVP, Chief Legal Officer, and Corporate Secretary, while Dr. Phoebe Mounts will no longer serve as the Company’s General Counsel. Ms. Zelnick Kaufman brings over two decades of legal, compliance, and operations experience in the life sciences industry, having served in leadership roles at Akorn Pharmaceuticals and Amneal Pharmaceuticals. CorMedix aims to launch DefenCath over the coming months and transition to a commercial stage entity.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.06%
Tags
management
CorMedix Inc

Nasdaq:CRMD

CRMD Rankings

CRMD Stock Data

321.09M
54.43M
1.01%
34.12%
15%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Berkeley Heights

About CRMD

cormedix inc. is a company based out of 745 route 202-206, suite 303, bridgewater, nj, united states.